Product Description
TRPM8 antagnonist (peipheral neuropathic pain); MT-8554 (Sourced from: https://www.mt-pharma.co.jp/e/develop/pipeline.html)
Mechanisms of Action: TRPM8 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mitsubishi Tanabe
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Japan
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Neuropathic Pain|Peripheral Nervous System Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2051210097 | P2 |
Completed |
Neuropathic Pain |
2022-11-08 |
|
| MT-8554-A-201 | P2 |
Completed |
Peripheral Nervous System Diseases |
2022-11-01 |
32% |